Literature DB >> 30010013

Roles of microRNA in prostate cancer cell metabolism.

Khanmi Kasomva1, Arnab Sen2, Michael Gabriel Paulraj3, Stephen Sailo4, Vandana Raphael5, Kekungu-U Puro2, Shiwoto Ruth Assumi6, Savarimuthu Ignacimuthu7.   

Abstract

MicroRNAs are non-coding RNA which functions as regulators of genes expression. MicroRNAs have shown their biological functions in cell proliferation, cell cycle, cell metabolism, apoptosis, invasion and metastasis. Cancer cells have the ability to grow in the absence of growth factors by increased metabolic activity. MicroRNAs regulate cell metabolic processes by targeting the key enzymes or transporters and change the metabolic activities by interfering with oncogenes/tumor suppressors, hypoxia, signalling pathways and cell adhesion. This review mainly explains the roles of microRNAs in prostate cancer cell metabolism, such as glucose uptake, glycolysis and lactate secretion, lipid metabolism and interaction with signalling pathways. The relation of microRNAs with hypoxia and cell adhesion in cell metabolism is also highlighted. Therefore, miRNAs help in regulating the metabolism of survived tumor cells, understanding such miRNA-mediated interaction could lead to new avenues in therapeutic application to treat PCa.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Glycolysis; Hypoxia; Metabolism; Prostate cancer; Signaling pathway; microRNAs

Mesh:

Substances:

Year:  2018        PMID: 30010013     DOI: 10.1016/j.biocel.2018.07.003

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  2 in total

1.  Astragalus Polysaccharides Inhibits Tumorigenesis and Lipid Metabolism Through miR-138-5p/SIRT1/SREBP1 Pathway in Prostate Cancer.

Authors:  Shanqi Guo; Baojie Ma; Xingkang Jiang; Xiaojiang Li; Yingjie Jia
Journal:  Front Pharmacol       Date:  2020-05-05       Impact factor: 5.810

2.  Retracted Article: Long noncoding RNA PCA3 regulates glycolysis, viability and apoptosis by mediating the miR-1/CDK4 axis in prostate cancer.

Authors:  Shuo Gu; Xiaobing Niu; Fei Mao; Zongyuan Xu
Journal:  RSC Adv       Date:  2018-11-08       Impact factor: 4.036

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.